These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

296 related items for PubMed ID: 14506041

  • 21. Synthesis, metabolic stability and antiviral evaluation of various alkoxyalkyl esters of cidofovir and 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine.
    Ruiz J, Beadle JR, Buller RM, Schreiwer J, Prichard MN, Keith KA, Lewis KC, Hostetler KY.
    Bioorg Med Chem; 2011 May 01; 19(9):2950-8. PubMed ID: 21493074
    [Abstract] [Full Text] [Related]

  • 22. Isolation and characterization of cidofovir resistant vaccinia viruses.
    Becker MN, Obraztsova M, Kern ER, Quenelle DC, Keith KA, Prichard MN, Luo M, Moyer RW.
    Virol J; 2008 May 14; 5():58. PubMed ID: 18479513
    [Abstract] [Full Text] [Related]

  • 23. Aerosolized cidofovir is retained in the respiratory tract and protects mice against intranasal cowpox virus challenge.
    Roy CJ, Baker R, Washburn K, Bray M.
    Antimicrob Agents Chemother; 2003 Sep 14; 47(9):2933-7. PubMed ID: 12936997
    [Abstract] [Full Text] [Related]

  • 24. Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.
    Quenelle DC, Prichard MN, Keith KA, Hruby DE, Jordan R, Painter GR, Robertson A, Kern ER.
    Antimicrob Agents Chemother; 2007 Nov 14; 51(11):4118-24. PubMed ID: 17724153
    [Abstract] [Full Text] [Related]

  • 25. Differential pathogenesis of cowpox virus intranasal infections in mice induced by low and high inoculum volumes and effects of cidofovir treatment.
    Smee DF, Gowen BB, Wandersee MK, Wong MH, Skirpstunas RT, Baldwin TJ, Hoopes JD, Sidwell RW.
    Int J Antimicrob Agents; 2008 Apr 14; 31(4):352-9. PubMed ID: 18206353
    [Abstract] [Full Text] [Related]

  • 26. Characterization and treatment of cidofovir-resistant vaccinia (WR strain) virus infections in cell culture and in mice.
    Smee DF, Wandersee MK, Bailey KW, Hostetler KY, Holy A, Sidwell RW.
    Antivir Chem Chemother; 2005 Apr 14; 16(3):203-11. PubMed ID: 16004083
    [Abstract] [Full Text] [Related]

  • 27. A single cidofovir treatment rescues animals at progressive stages of lethal orthopoxvirus disease.
    Israely T, Paran N, Lustig S, Erez N, Politi B, Shafferman A, Melamed S.
    Virol J; 2012 Jun 18; 9():119. PubMed ID: 22709563
    [Abstract] [Full Text] [Related]

  • 28. Cidofovir in the treatment of poxvirus infections.
    De Clercq E.
    Antiviral Res; 2002 Jul 18; 55(1):1-13. PubMed ID: 12076747
    [Abstract] [Full Text] [Related]

  • 29. Increased antiviral activity of 1-O-hexadecyloxypropyl-[2-(14)C]cidofovir in MRC-5 human lung fibroblasts is explained by unique cellular uptake and metabolism.
    Aldern KA, Ciesla SL, Winegarden KL, Hostetler KY.
    Mol Pharmacol; 2003 Mar 18; 63(3):678-81. PubMed ID: 12606777
    [Abstract] [Full Text] [Related]

  • 30. Evaluation of nucleoside phosphonates and their analogs and prodrugs for inhibition of orthopoxvirus replication.
    Keith KA, Hitchcock MJ, Lee WA, Holý A, Kern ER.
    Antimicrob Agents Chemother; 2003 Jul 18; 47(7):2193-8. PubMed ID: 12821467
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model.
    Buller RM, Owens G, Schriewer J, Melman L, Beadle JR, Hostetler KY.
    Virology; 2004 Jan 20; 318(2):474-81. PubMed ID: 14972516
    [Abstract] [Full Text] [Related]

  • 35. Lack of efficacy of aurintricarboxylic acid and ethacrynic acid against vaccinia virus respiratory infections in mice.
    Smee DF, Hurst BL, Wong MH.
    Antivir Chem Chemother; 2010 Apr 14; 20(5):201-5. PubMed ID: 20413827
    [Abstract] [Full Text] [Related]

  • 36. Inhibition of cowpox virus and monkeypox virus infection by mitoxantrone.
    Altmann SE, Smith AL, Dyall J, Johnson RF, Dodd LE, Jahrling PB, Paragas J, Blaney JE.
    Antiviral Res; 2012 Feb 14; 93(2):305-308. PubMed ID: 22182595
    [Abstract] [Full Text] [Related]

  • 37. Postexposure prevention of progressive vaccinia in SCID mice treated with vaccinia immune globulin.
    Fisher RW, Reed JL, Snoy PJ, Mikolajczyk MG, Bray M, Scott DE, Kennedy MC.
    Clin Vaccine Immunol; 2011 Jan 14; 18(1):67-74. PubMed ID: 21106779
    [Abstract] [Full Text] [Related]

  • 38. Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney.
    Ciesla SL, Trahan J, Wan WB, Beadle JR, Aldern KA, Painter GR, Hostetler KY.
    Antiviral Res; 2003 Aug 14; 59(3):163-71. PubMed ID: 12927306
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Oral treatment of murine cytomegalovirus infections with ether lipid esters of cidofovir.
    Kern ER, Collins DJ, Wan WB, Beadle JR, Hostetler KY, Quenelle DC.
    Antimicrob Agents Chemother; 2004 Sep 14; 48(9):3516-22. PubMed ID: 15328119
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.